Current efforts to protect hosts against bacterial infection through the development of vaccines suffer from an absence of fundamental information about detailed immune responses. Host factors leading to the development of protective antibodies such as the antibody isotype, subclass and affinity largely are uncharacterized. The chemical characterization of what constitutes an immunogenic determinant on the bacterial surface has not been defined. In this grant we propose to analyze chemically and immunologically host and parasite factors which mediate protective immunity and will serve as the basis for developing a new class of bacterial vaccines, oligasaccharide protein conjugates. Our attention over the past several years has focused on the immunochemistry of group B Streptococcus GBS type specific polysaccharides. The proposed study is a fundamental investigation into specific interactions between oligosaccharide haptens derived from GBS polysaccharides and immunoglobulins. Critical to our study will be the preparation of oligosaccharides from type III specific polysaccharide. These oligosaccharides will be characterized chemically and modified structurally to produce a series of oligosaccharide fragments which will serve as haptens. These oligosaccharides will differ in critical structures which will facilitate determination of immunospecificity. Using thes oligosaccharides coupled to protein carriers, specific antibodies will be purified by affinity chromatography. Physical-chemical and immunological studies of the interactions of oligosaccharides and monoclonal antibodies will be performed. These studies will define the immunodeterminants on oligosaccharide utilizing monoclonal antibodies. We will characterize the isotype, subclass and affinity of protective antibodies in human sera from naturally acquired infection and following vaccination. Thes oligosaccharide-protein conjugates will be studied for immunogenicity and protection in an animal model of type III GBS infection. Conjugate vaccines will be constructed to determine optimal carbohydrate chain length and density of coupling. The knowledge gained will be essential in developing bacterial vaccines in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI023339-01
Application #
3135304
Study Section
Bacteriology and Mycology Subcommittee 1 (BM)
Project Start
1985-09-01
Project End
1987-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
Baker, Carol J; Carey, Vincent J; Rench, Marcia A et al. (2014) Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 209:781-8
Wang, Julia Y; Chang, Alex H C; Guttormsen, Hilde-Kari et al. (2003) Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling. Vaccine 21:1112-7
Paoletti, Lawrence C; Kasper, Dennis L (2003) Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 3:975-84
Pozdnyakova, Olga; Guttormsen, Hilde-Kari; Lalani, Farah N et al. (2003) Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 170:84-90
Tettelin, Herve; Masignani, Vega; Cieslewicz, Michael J et al. (2002) Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A 99:12391-6
Henneke, Philipp; Takeuchi, Osamu; Malley, Richard et al. (2002) Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J Immunol 169:3970-7
Brigtsen, Anne Karin; Kasper, Dennis L; Baker, Carol J et al. (2002) Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis 185:1277-84
Guttormsen, Hilde-Kari; Baker, Carol J; Nahm, Moon H et al. (2002) Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun 70:1724-38
Henneke, P; Takeuchi, O; van Strijp, J A et al. (2001) Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J Immunol 167:7069-76
Zou, W; Li, J; Larocque, S et al. (2001) Construction of multivalent sialyl Le(x) from the type Ia group B Streptococcus capsular polysaccharide. Carbohydr Res 332:249-55

Showing the most recent 10 out of 48 publications